Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas

D. L. Persons, L. C. Hartmann, J. F. Herath, T. J. Borell, William Arthur Cliby, Gary Keeney, Robert Brian Jenkins

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled α-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.

Original languageEnglish (US)
Pages (from-to)733-741
Number of pages9
JournalAmerican Journal of Pathology
Volume142
Issue number3
StatePublished - 1993

Fingerprint

erbB-2 Genes
Cytogenetic Analysis
Interphase
Centromere
Fluorescence In Situ Hybridization
Carcinoma
Gene Amplification
Chromosomes
Metaphase
Chromosomes, Human, Pair 16
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 8
Neoplasms
Chromosomes, Human, Pair 10
Chromosomes, Human, Pair 17
Ploidies
Touch
Cell Nucleus
Karyotype
Color

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. / Persons, D. L.; Hartmann, L. C.; Herath, J. F.; Borell, T. J.; Cliby, William Arthur; Keeney, Gary; Jenkins, Robert Brian.

In: American Journal of Pathology, Vol. 142, No. 3, 1993, p. 733-741.

Research output: Contribution to journalArticle

Persons, D. L. ; Hartmann, L. C. ; Herath, J. F. ; Borell, T. J. ; Cliby, William Arthur ; Keeney, Gary ; Jenkins, Robert Brian. / Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas. In: American Journal of Pathology. 1993 ; Vol. 142, No. 3. pp. 733-741.
@article{f19e9ecfaa9d4a2189dc656352b60089,
title = "Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas",
abstract = "Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled α-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.",
author = "Persons, {D. L.} and Hartmann, {L. C.} and Herath, {J. F.} and Borell, {T. J.} and Cliby, {William Arthur} and Gary Keeney and Jenkins, {Robert Brian}",
year = "1993",
language = "English (US)",
volume = "142",
pages = "733--741",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas

AU - Persons, D. L.

AU - Hartmann, L. C.

AU - Herath, J. F.

AU - Borell, T. J.

AU - Cliby, William Arthur

AU - Keeney, Gary

AU - Jenkins, Robert Brian

PY - 1993

Y1 - 1993

N2 - Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled α-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.

AB - Karyotype information on ovarian carcinomas has been limited because the tumors are often difficult to culture and the resultant metaphases can have complex numerical and structural chromosomal anomalies. Fluorescent in situ hybridization is a rapid method of determining centromere copy number in metaphase cells and interphase nuclei. Fluorescent in situ hybridization was used to determine the numerical centromere complement of chromosomes X, 8, 12, and 17 and HER-2/neu gene amplification within interphase nuclei of 25 primary epithelial ovarian carcinomas. Touch preparations of the carcinomas were hybridized with two-color combinations of directly labeled α-satellite centromeric chromosome enumeration probes and a directly labeled HER-2/neu probe. Modal centromere copy numbers for each of the four chromosomes were used to determine numerical abnormalities relative to the flow cytometric DNA ploidy level for each tumor. Four cases were found to be normal with respect to the four chromosomes studied. In the remaining 21 cases a relative loss of chromosomes 17 (16 cases) and X (nine cases) and a relative gain of chromosomes 12 (10 cases) and 8 (nine cases) were the most common findings. In addition, the HER-2/neu gene was amplified in two of the 25 tumors. In conclusion, fluorescent in situ hybridization is an excellent method for rapid determination of numerical abnormalities and gene amplification in ovarian carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=0027769626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027769626&partnerID=8YFLogxK

M3 - Article

C2 - 8096121

AN - SCOPUS:0027769626

VL - 142

SP - 733

EP - 741

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -